Company Bicycle Therapeutics plc

Equities

BCYC

US0887861088

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Bicycle Therapeutics plc

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
22.19 ^USD	+1.56%		-3.65%	+22.73%

May. 29	European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	MT
May. 24	European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	MT

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Number of employees: 284

USD in Million	2022	Weight	2023	Weight	Delta
Chemically Synthesized Medicines 100.0 %	14	100.0 %	27	100.0 %	+86.52%

USD in Million	2022	Weight	2023	Weight	Delta
United Kingdom 100.0 %	14	100.0 %	27	100.0 %	+86.52%

Managers	Title	Age	Since
Kevin Lee CEO	Chief Executive Officer	55	15-08-31
Alethia Young DFI	Director of Finance/CFO	45	23-07-16
Alistair Milnes COO	Chief Operating Officer	50	20-12-31
Michael Skynner CTO	Chief Tech/Sci/R&D Officer	55	15-12-31
Nicholas Keen CTO	Chief Tech/Sci/R&D Officer	56	16-12-31
Travis Thompson AUD	Comptroller/Controller/Auditor	-	18-03-31
Jennifer Perry PRN	Corporate Officer/Principal	-	-
Zafar Qadir LAW	General Counsel	-	20-04-22
Santiago Arroyo PRN	Corporate Officer/Principal	64	23-03-30
Nigel Crockett PRN	Corporate Officer/Principal	59	19-10-28

Members of the board	Title	Age	Since
Pierre Legault CHM	Chairman	63	19-03-17
Jose-Carlos Gutiérrez-Ramos BRD	Director/Board Member	61	21-03-16
Richard Kender BRD	Director/Board Member	68	19-07-23
Janice Bourque BRD	Director/Board Member	67	19-07-17
Gregory Winter FOU	Founder	73	08-12-31
Kevin Lee CEO	Chief Executive Officer	55	15-08-31
Stephen Sands BRD	Director/Board Member	67	Feb. 19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	38,073,148	4,333,333 ( 11.38 %)	0	11.38 %

Name	Equities	%	Valuation
Baker Bros. Advisors LP 18.48 %	7,017,176	18.48 %	158 M $
Baker Bros. Advisors LP 13.02 %	4,942,823	13.02 %	111 M $
Deep Track Capital LP 9.193 %	3,490,506	9.193 %	79 M $
Paradigm BioCapital Advisors LP 8.551 %	3,246,759	8.551 %	73 M $
Armistice Capital LLC 4.404 %	1,672,000	4.404 %	38 M $
Tybourne Capital Management (HK) Ltd. 4.069 %	1,545,026	4.069 %	35 M $
Morgan Stanley Capital Services LLC 3.995 %	1,516,715	3.995 %	34 M $
First Light Asset Management LLC 3.142 %	1,193,051	3.142 %	27 M $
Westfield Capital Management Co. LP 2.736 %	1,038,917	2.736 %	23 M $
POLAR CAPITAL HOLDINGS PLC 2.646 %	1,004,535	2.646 %	23 M $

Name	Equities	%	Valuation
Cambridge Innovation Capital Ltd 5.917 %	1,751,437	5.917 %	39 M $
GSK PLC 5.168 %	1,529,561	5.168 %	34 M $
Baker Bros. Advisors LP 2.789 %	825,418	2.789 %	19 M $
Kevin Lee 1.308 %	387,270	1.308 %	9 M $
Gregory Winter 0.6104 %	180,677	0.6104 %	4 M $
Michael Skynner 0.3206 %	94,884	0.3206 %	2 M $
Alistair Milnes 0.2441 %	72,241	0.2441 %	2 M $
Nicholas Keen 0.2358 %	69,803	0.2358 %	2 M $
Nigel Crockett 0.1614 %	47,761	0.1614 %	1 M $
Santiago Arroyo 0.1318 %	39,000	0.1318 %	878 280 $

Name	Equities	%	Valuation
Baker Bros. Advisors LP 50.63 %	2,382,784	50.63 %	60 M $

Bicycle Therapeutics Plc

Granta Park Great Abington Portway Building

CB21 6GS, Cambridge

+44 1223 261 503

http://bicycletherapeutics.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.19 USD

Average target price

42.4 USD

Spread / Average Target

+91.08%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BICYCLE THERAPEUTICS PLC	+22.73%	1.53B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.17%	21.96B
GENMAB A/S	-8.14%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B
INSMED INCORPORATED	+77.64%	8.87B

Bio Therapeutic Drugs